Centro Clinico Nemo
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan, Italy
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
The research at Centro Clinico Nemo emphasizes rare genetic disorders that affect muscle development and function, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Myotonic Dystrophy. Trials aim to test novel gene‑based and protein‑restoring therapies while monitoring safety and tolerability.
- Gene‑editing approaches for DMD
- Antisense oligonucleotide studies in SMA
- Small‑molecule modifiers for myotonia
- Long‑term safety monitoring of emerging treatments
Ongoing studies provide hope for patients and families by seeking to improve motor outcomes and quality of life in these congenital conditions.
Musculoskeletal Diseases
Investigations target progressive muscle‑wasting conditions such as Facioscapulohumeral Muscular Dystrophy and amyotrophic lateral sclerosis, focusing on slowing decline and preserving strength. The primary goal is to evaluate efficacy of investigational drugs that modulate muscle metabolism or reduce pathological protein aggregation.
- HDAC inhibition in non‑ambulant DMD
- Anti‑inflammatory agents for FSHD
- Neuroprotective compounds for ALS
- Functional mobility assessments in trial cohorts
By integrating imaging biomarkers and functional tests, the site aims to generate robust data that could translate into better therapeutic options for patients with debilitating muscle disorders.
Nervous System Diseases
The center conducts trials on neurodegenerative illnesses such as Amyotrophic Lateral Sclerosis and advanced forms of Spinal Muscular Atrophy, seeking to halt neuronal loss and improve respiratory and motor function. Research emphasizes safety, pharmacokinetics, and measurable clinical benefit of emerging agents.
- Combination therapy of risdiplam with novel agents
- High‑dose intrathecal nusinersen evaluations
- Metabolic support with acetyl‑L‑carnitine in ALS
- Biomarker development using MRI and functional scales
These studies contribute to a deeper understanding of disease mechanisms and strive to deliver treatments that extend survival and independence for affected individuals.
Musculoskeletal and Neural Physiological Phenomena
A dedicated research stream investigates the underlying physiology of muscle and nerve interaction, employing advanced imaging and electrophysiological tools to assess treatment impact. Projects explore how investigational compounds influence muscle protein expression, myotonia, and neural signaling pathways.
- MRI‑based quantification of muscle composition
- Electromyography for myotonia severity
- Pharmacodynamic profiling of RO7204239
- Biomarker validation for therapeutic response
Insights gained from these mechanistic studies support the design of more effective interventions across the site’s broader neuromuscular program.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Avidity Biosciences Inc.3active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Avidity Biosciences Inc.5trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Clinico Nemo
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years | Sarepta Therapeutics Inc. | Phase I/II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Givinostat | 3 | Unknown | 2017-10-19 | 2024-11-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.